A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery

Summary

This open-label study will evaluate efficacy, safety and tolerability of RO5045337 in patients with liposarcoma who are eligible for debulking surgery. Prior to surgery, patients will receive 2-3 cycles of RO5045337, orally for 10 days followed by 18 days of rest per cycle. Anticipated time on study treatment is 3 months. Patients with an incomplete resection may be treated for an additional 3 cycles with RO5045337.

Timeline

Start

2010-06

Primary completion

2011-03

Completion

2011-03

Drugs

Indications